By Ahmed Aboulenein WASHINGTON (Reuters) – The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzhei[...]
Read more
Updated
Oil drops on China uncertainty; U.S. demand limits decline
By Shariq Khan NEW YORK (Reuters) – Oil prices fell for a second straight session on Thursday on an uncertain demand outlook as more countries considered restrictions on Chinese travelers with C[...]
Read more
TSMC starts volume production of most advanced chips in Taiwan
TAINAN, Taiwan (Reuters) -Chipmaker Taiwan Semiconductor Manufacturing Company Ltd (TSMC) began mass production of its most advanced chips in southern Taiwan on Thursday and the company’s chairm[...]
Read more
Wall St ends firmer, growth stocks lead in thin trading
By Echo Wang (Reuters) – Wall Street’s main indexes closed higher on Thursday, led by growth stocks in light trading, as U.S. unemployment data signaled the Federal Reserve’s interes[...]
Read more
U.S. Treasury says consumer leases can qualify for EV tax credits
By David Shepardson (Reuters) -The U.S. Treasury Department said on Thursday that electric vehicles leased by consumers can qualify starting Jan. 1 for up to $7,500 in commercial clean vehicle tax cre[...]
Read more
Wall Street surges in dip-buying rally, oil falls
By Stephen Culp NEW YORK (Reuters) – U.S. stocks closed sharply higher on Thursday, powered by a rebound in recently battered mega-cap growth stocks, while crude oil prices declined as a surge o[...]
Read more
FTX customers ask bankruptcy court to keep their names secret
By Dietrich Knauth (Reuters) – A group of FTX customers from outside the United States have asked a U.S. bankruptcy judge to keep their names secret during the cryptocurrency exchange’s ba[...]
Read more
TC Energy says Keystone pipeline returns to service
(Reuters) -Canadian pipeline operator TC Energy Corp said on Thursday it had completed a controlled restart of its Keystone crude oil pipeline to Cushing, Oklahoma, safely returning the pipeline to se[...]
Read more
Novartis to pay $245 million to end antitrust cases over Exforge drug generics
By Jonathan Stempel NEW YORK (Reuters) -Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United Stat[...]
Read more